GENES ENCODING MYCOBACTERIAL PROTEINS ASSOCIATED WITH CELL BINDING AND CELL ENTRY AND USES THEREOF

Abstract: A gene from a strain of Mycobacterium encoding a protein of molecular weight between about 45 to about 60 kDa and associated with cell binding and cell entry or fragment thereof was cloned. The genes and encoded protein have utility in immunogenic preparations or diagnostic applications.

Description: TITLE OF INVENTION GENES ENCODING MYCOBACTERIAL PROTEINS ASSOCIATED WITH CELL BINDING AND CELL ENTRY AND USES THEREOF FIELD OF INVENTION The present invention relates to the field of molecular biology and is particularly concerned with genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof. REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of copending United States Patent Application No. 08/677,970 filed July 10, 1996. BACKGROUND OF THE INVENTION Tuberculosis (TB) is a major cause of mortality throughout the world, particularly in developing countries. There are about 8 to 9 million new cases of clinical disease reported every year and the number of deaths is estimated to be about 3 million. In the U.S. the trend of steady decline in TB has reversed and the problem is compounded by increasing numbers of drug- resistant strains. The tuberculosis complex is a group of four mycobacterial species that are genetically closely related. The three most important members are Mycobacterium tuberculosis, the major cause of human TB; Mycojacteriu-i! a-f.rica.num, a major human pathogen in some populations; and Mycobacterium bovis, the cause of bovine TB. None of these mycobacteria is restricted in being pathogenic for a single host species. In addition to being an important human disease, TB is also a major veterinary problem in many countries. Infection of cattle with M. bovis results in bovine TB and all animals showing any signs of infection are systematically slaughtered. The economic losses are thus extensive, and furthermore, cattle can serve as a reservoir for human disease. In a majority of cases of infection, inhaled tubercle bacilli are ingested by phagocytic alveolar macrophages and are either killed or grow intracellularly to a limited extent in local lesions called tubercles. In this way the infection is limited and the primary sites of infection are walled off without any symptoms of disease being observed. Such individuals have a lifetime risk of about 10% for developing active disease. In a latter eventuality, bacilli spread from the site of infection in the lung, through the lung and via lymphatics or blood to other parts of the body producing characteristic solid caseous (cheese-like) necrosis in which bacilli survive. If the necrotic reaction expands breaking into a bronchus, or in the worst case, if the solid necrosis liquefy, a rapid proliferation of the bacilli occurs. The pathological and inflammatory processes set in motion then produce the characteristic weakness, fever, chest pain, cough and bloody sputum which are the hallmarks of active TB. Effective treatment of TB with antibiotics exists. However, this is expensive and requires prolonged administration of a combination of drugs. There is a problem in compliance with the drug administration regime because of the extended time periods involved and this has contributed to the appearance of drug resistant strains. There is a recognized vaccine for TB which is an attenuated form of M. bovis, known as BCG (bacilla Calmette Guerin) . This strain was developed in 1921 and the basis for its attenuation is still not known (ref. 1 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosure of these references are hereby incorporated by reference into the present disclosure) . The efficacy of BCG as a TB vaccine is a subject of controversy and has been estimated in various trials to be anywhere between 0 and 70%. The molecular basis for the virulence and pathogenesis of M. tuberculosis have not been extensively described. Some virulence factors, particularly those related to the sigma factors have been recently identified (ref . 2) . M. tuberculosis can enter non-phagocytic cells in culture, such as HeLa cells (ref. 3) and once inside can multiply and survive. Recently, a DNA molecule (1535 bp long) from a strain of M. tuberculosis (H37Ra) was reported to mediate the entry of the bacterium and its survival in mammalian cells (ref. 4) . This DNA fragment when introduced into a non-pathogenic strain of E. coli is able to confer invasiveness to the bacterium, and survival for up to 24 hours in human macrophages. The race gene (mycobacterial cell entry) gene was mapped to an Open Reading Frame (ORF) extending from position 182 to 810 on the 1535bp DNA fragment mentioned above and encodes a protein of molecular weight between 22 and 27 kDa. Mycobacterial infection may lead to serious disease. It would be advantageous to provide genes encoding proteins of mycobacteria associated with cell binding and cell entry for the provision of these proteins as antigens in immunogenic preparations including vaccines, carriers for other materials including antigens and the generation of diagnostic reagents. The genes encoding mycobacterial proteins associated with cell binding and cell entry are particularly desirable and useful in the specific identification and diagnosis of mycobacteria and for immunization against disease caused by mycobacterial infection. SUMMARY OF INVENTION In the present invention, the gene of Mycobacterium bovis encoding the protein associated with cell binding and cell entry has been isolated and cloned and found to encode a protein of molecular weight about 45 to about 60 kDa. Corresponding genes have been detected in other members of the tuberculosis complex, including -Myco-bacterium tuberculosis. Accordingly, in one aspect of the invention, there is provided an isolated nucleic acid molecule encoding a Mycobacterium protein having a molecular weight of about 45 to about 60 kDa associated with cell binding and cell entry of a Mycobacterium strain or a fragment of said protein. The Mycobacterium strain is a strain of the tuberculosis complex, which includes a strain of M. tuberculosis and M. bovis as well as the other members of the complex, including M. africanum . The protein associated with cell binding and cell entry encoded by the nucleic acid molecule may have an amino acid composition as shown in Table 2. The nucleic acid molecule of the invention may have a restriction map as shown in Figure 5. This restriction map is for the gene from the M. bovis strain BCG. The nucleic acid molecule also may have the restriction map of the corresponding genes in other mycobacteria from the tuberculosis complex. The nucleic acid molecule may have a DNA sequence as shown in Figure 6 (SEQ ID No: 2) for M. bovis strain BCG or the sequence of the corresponding gene in other mycobacteria from the tuberculosis complex. The nucleic acid molecule also may encode an amino acid sequence as shown in Figure 7 (SEQ ID No: 3) for M. bovis strain BCG or the sequence encoding the corresponding protein in other mycobacteria from the tuberculosis complex. In another aspect of the invention, there is provided an isolated DNA molecule amplifiable by polymerase chain reaction (PCR) by a pair of primers having the sequence of primers 4879 (SEQ ID No: 12) and 4882 (SEQ ID No: 15); or 4879 (SEQ ID No: 12) and 4865 (SEQ ID No: 11); or 4879 (SEQ ID No: 12) and 4812 (SEQ ID No: 10); or 5' primer SEQ ID NO: 19 and 3' primer SEQ ID NO: 18; or 5' primer SEQ ID NO: 20 and 3' primer SEQ ID NO: 18; or 5' primer SEQ ID NO: 21 and 3' primer SEQ ID NO: 18; or 5' primer SEQ ID NO: 22 and 3' primer SEQ ID NO: 18. The DNA molecule may be from a member of the tuberculosis complex, particularly M. tuberculosis and M. bovis . In an additional aspect, the present invention includes a vector adapted for transformation of a host, comprising a nucleic acid molecule or DNA molecule provided herein. The invention further includes a plasmid containing the gene of a strain of Mycobacterium encoding the protein associated with cell binding and cell entry having the identifying characteristics of plasmid pBCGcepX having ATCC Deposit No. 97511. The vector may be adapted for expression of the encoded protein in a heterologous or homologous host, in either a lipidated or non-lipidated form. Accordingly, a further aspect of the present invention provides an expression vector adapted for transformation of a host comprising a nucleic acid molecule or DNA molecule as provided herein and expression sequences operatively coupled to the nucleic acid molecule or DNA molecule for expression by the host of the protein associated with cell binding and cell entry. The expression sequences may include a promoter and a nucleic acid portion encoding a leader sequence for secretion from the host of the protein. The expression sequences may also include a nucleic acid portion encoding a lipidation signal for expression from the host of a lipidated form of the protein. The host may be selected from, for example, Escherichia coli , Bordetella , Ba cillus, Haemophilus , Moraxella, fungi, yeast or baculovirus and Semliki Forest virus expression systems may be used. In an additional aspect of the invention, there is provided a transformed host containing an expression vector as provided herein. The invention further includes a recombinant mycobacterial protein associated with cell binding and cell entry producible by the transformed host as provided herein or a fragment of the protein. In accordance with another aspect of the invention, an immunogenic composition is provided which comprises at least one active component which is a nucleic acid molecule, DNA molecule or protein as provided herein and a pharmaceutically acceptable carrier therefor or vector therefor. The at least one active component produces an immune response when administered to a host. The immunogenic compositions provided herein may be formulated as vaccines for in vivo administration to a host. For such purpose, the compositions may be formulated as a microparticle, capsule, ISCOM or liposome preparation. The immunogenic composition may be provided in combination with a targeting molecule for delivery to specific cells of the immune system or to mucosal surfaces. The immunogenic compositions of the invention (including vaccines) may further comprise at least one other immunogenic or immunostimulating material and the immunostimulating material may be at least one adjuvant or at least one cytokine. In accordance with another aspect of the invention, there is provided a method for generating an immune response in a host, comprising the step of administering to a susceptible host, such as a primate including a human, an effective amount of the immunogenic composition as recited above. The immune response may be a humoral or a cell-mediated immune response and may provide protection against disease caused by mycobacteria. In a further aspect, there is provided a live vector for delivery of the mycobacterial protein associated with cell binding and cell entry to a host, comprising a vector containing the nucleic acid molecule or DNA molecule as described above. The vector may be selected from Salmonella , adenovirus, poxvirus, vaccinia and poliovirus. The nucleic acid and DNA molecules provided herein are useful in diagnostic applications. Accordingly, in a further aspect of the invention, there is provided a method of determining the presence, in a sample, of nucleic acid encoding a mycobacterial protein associated with cell binding and cell entry, comprising the steps of: (a) contacting the sample with a nucleic acid or DNA molecule as provided herein to produce duplexes comprising the nucleic acid or DNA molecule and any nucleic acid molecule encoding the protein present in the sample and specifically hybridizable therewith; and (b) determining the production of the duplexes. In addition, the present invention provides a diagnostic kit for determining the presence, in a sample, of nucleic acid encoding protein of a strain of Mycobacterium associated with cell binding and cell entry, comprising: (a) a nucleic acid or DNA molecule as provided herein; (b) means for contacting the nucleic acid or DNA molecule with the sample to produce duplexes comprising the nucleic acid or DNA molecule and any nucleic acid encoding the protein present in the sample and hybridizable with the nucleic acid or DNA molecule; and (c) means for determining production of the duplexes . The present invention additionally includes the use of a gene amplification detection assay for the detection of mycobacteria. Accordingly, in this aspect of the invention, there is provided a method for the detection of a species of mycobacteria in a sample such as tissue or body fluids, which comprises: providing a pair of primers which are primers 4879 (SEQ ID No: 12) and 4882 (SEQ ID No: 15); or 4879 (SEQ ID No. 12) and 4865 (SEQ ID No: 11); or 4879 (SEQ ID No: 12) and 4812 (SEQ ID No: 10); contacting the sample with the primers; performing a poly erase chain reaction to amplify an amplifiable DNA sequence encoding a mycobacterial protein associated with cell binding or cell entry, and detecting the amplified DNA sequence which indicates the presence of a species of Mycobacterium in the sample. The present invention further includes, in a further aspect, an oligonucleotide primer selected from the group consisting of primers 4879 (SEQ ID No: 12), 4882 (SEQ ID No: 15), 4865 (SEQ ID No: 11) and 4812 (SEQ ID No: 10) . In addition, the present invention includes, in a further aspect, a method of forming a substantially pure recombinant mycobacterial protein associated with cell binding and cell entry or fragment thereof which comprises transforming a host with a vector as described above, growing the transformed host to express the protein and isolating and purifying the protein free from other proteinaceous and cellular material. The protein fragment may be expressed from a vector containing a gene having a 5 * -truncation to a start codon. In a further aspect of the invention, there is provided an isolated and purified mycobacterial protein of a Mycobacterium species associated with cell binding and cell entry having a molecular weight of about 45 to about 60 kDa. Such protein may be derived from the Mycobacterium, or by recombinant means as described above . The proteinaceous material provided herein also may be included in the immunogenic composition as the active component thereof. The invention further includes the use of the nucleic acid molecules, DNA molecules and proteins provided herein as medicines. The invention additionally includes the use of the nucleic acid molecules, DNA molecules and proteins provided herein as an active pharmaceutical substance and in the preparation of medicaments for protection against disease caused by infection by Mycobacterium . Advantages of the present invention include: an isolated and purified nucleic acid molecule encoding a mycobacterial protein of a strain of Mycobacterium associated with cell binding and cell entry; Mycobacterial proteins associated with cell binding and cell entry; and diagnostic kits and immunological reagents for specific identification of mycobacteria. BRIEF DESCRIPTION OF DRAWINGS The present invention will be further understood from the following General Description and specific Examples with reference to the drawings, in which: Figure 1, containing panels A, B and C shows the amplification of genes encoding mycobacterial proteins associated with cell binding and cell entry by the polymerase chain reaction procedure; Figure 2, containing panels (A) and (B) , shows a Southern blot analysis of the genes encoding mycobacterial proteins associated with cell binding and cell entry; Figure 3 illustrates plasmids containing genes encoding mycobacterial proteins associated with cell binding and cell entry; Figure 4 shows the nucleotide sequence (SEQ ID No: 1) of a DNA molecule containing the gene encoding the mycobacterial protein associated with cell binding and cell entry; Figure 5 shows a restriction enzyme analysis of the gene encoding the mycobacterial protein associated with cell binding and cell entry; Figure 6 shows the coding sequence (SEQ ID No: 2) of the gene encoding the mycobacterial protein associated with cell binding and cell entry; Figure 7 shows the nucleotide sequence (SEQ ID No: 2) and the deduced amino acid sequence (SEQ ID No: 3) of the mycobacterial protein associated with cell binding and cell entry; Figure 8 shows a comparison of the DNA sequences of the M. bovis gene encoding a mycobacterial protein associated with cell binding and cell entry (BCGINV-33) (SEQ ID No: 2) and a DNA fragment of M. tuberculosis described in the art (MTMCE) (SEQ ID No: 17); Figure 9 shows the identification of genes encoding the mycobacterial protein associated with cell binding and cell entry in clinical isolates of M. tuberculosis; Figure 10 shows the further characterization of genes encoding the mycobacterial protein associated with cell binding and cell entry in other strains of Mycobacterium tuberculosis; Figure 11, containing panels A and B, shows the specific identification of mycobacteria from other bacteria; Figure 12 shows expression plasmids containing the genes encoding mycobacteria protein associated with cell binding and cell entry, in the form of the full length gene and three truncations thereof from the 5 ' -end of the gene; Figure 13, comprising panels A and B, contains Western blots of the expression of mycobacterial protein associated with cell binding and cell entry and truncations thereof from the expression plasmids of Figure 12, effected on whole cell extracts (Panel A) and pelleted inclusion bodies (Panel B) ; and Figure 14, comprising panels A and B, contains electron micrographs of HeLa cells which have been incubated with protein coated latex beads. Panel A shows a HeLa cell where the protein is the mycobacterial protein associated with cell binding and cell entry showing invasion of the cell (arrow) . Panel B shows a HeLa cell wherein the protein bovine serum albumin (BSA) showing no cell invasion. GENERAL DESCRIPTION OF THE INVENTION Referring to Figure 1, there is illustrated the PCR amplification of the gene encoding the mycobacterial protein associated with cell binding and cell entry from M. bovis BCG. The gene is sometimes referred to herein as the mce gene. The mycobacterial protein associated with cell binding and cell entry is sometimes referred to herein as mcep. The sequence of the various primers shown in Figure 1 are listed in Table 1 below. Two primers, 4676 (SEQ ID No: 4) and 4677 (SEQ ID No: 5) corresponding to the 5' and 3' ends of the ORF1 sequence (181 bp to 810 bp) encoding the mce of MycoJacterium tuberculosis, which is part of the 1535 bp insert, were designed according to the sequence published by Arruda et al (ref. 4) to amplify the corresponding race gene from BCG. PCR experiments with BCG DNA and subsequent electrophoresis did not yield the expected DNA band (panel A, Lane 2; panel B, Lane 2; Figure 1), whereas the control plasmid pZX7, (labelled as pBmce Lane 1, panel A, Figure 1) gave the expected amplification product. Another pair of oligomers, 4414 (SEQ ID No: 6) and 4448 (SEQ ID No: 9), which prime in the ORF at sequences a few bases removed from the ends (approximately 20), do give the expected product of the correct size for both BCG and the control plasmid. Other amplifications were carried out using primer pairs 4676 (SEQ ID No: 4)/ 4448 (SEQ ID No: 9), 4414 (SEQ ID No: 6)/ 4447 (SEQ ID No: 8) and 4415 (SEQ ID No: 16)/ 4447 (SEQ ID No: 8) , the products were analyzed by gel electrophoresis and the results shown in Figure 1. Only primer pairs 4676/4448 and 4414/4448 yield expected amplification products from PCR reactions on BCG DNA, based on the published Mycobacterium tuberculosis mce gene sequence. The control experiments using plasmid pZX7 (labelled as pBmce or "plasmid" in Figure 1) all gave the expected sized amplified fragment. To clone the corresponding gene from M. bovis BCG, the gene was identified on particular fragments of the M. bovis genome by Southern blot hybridization using an race gene-specific probe. Restriction enzyme digestion of M. bovis BCG DNA and subsequent Southern blot analysis using a PCR amplified product (primer pairs 4414/4448; Lane 2; panel A, Figure 1) as a probe, indicated the presence of the race gene on 1.5 kb and 5 kb fragment of Sal I and Xho I digests (Figure 2) . The corresponding bands were cut out and ligated into suitably digested pUC18 and pBluescript II sk(+) plasmids respectively. The libraries obtained after transformation of competent E . coli cells were probed for the race gene by hybridization and two positive clones were identified. These clones were grown, plasmid isolated and analyzed to yield two plasmids: plasmid pBCGcepX contained an approximately 5 kb DNA insert hybridizing to race gene-specific probe and another plasmid pBCGcepS containing a 1.5 kb Sal I insert also hybridizing to the mce gene-speci ic probe (Figure 3) . The inserts of plasmids pBCGcepS and pBCGcepX were sequenced by the primer walking technique. Plasmid pBCGcepS contained a 1.5 kb insert (shown in dark box, Figure 3) containing the M. bovis BCG gene and also an irrelevant tandem 1.5 kb Sal I insert (shown in grey box, Figure 3) . The sequence data from the inserts were aligned using a sequence assembly program from Intelligenetics. It was found that the 1.5 kb Sail insert of pBCGcepS was an internal fragment of the larger pBCGcepX clone. The complete sequence of the 4740 bp DNA fragment cloned into plasmid pBCGcepX (SEQ ID No: 1) is illustrated in Figure 4. The ORF of the race gene of Mycojacteriura tuberculosis previously described (ref. 4) is an internal sequence of the BCG gene provided herein. The corresponding Mycobacterium tuberculosis ORF starts at position 2336 and is identical to the M. bovis BCG sequence for the next 602 bp. The two sequences then diverge and the Mycobacterium tuberculosis sequence ends in a stop codon 21bp along, whereas, the BCG ORF continues for another 423 bp. The putative start of the M. bovis BCG gene is also 505 bp upstream of the GTG start sequence of the Mycojbacteriura tuberculosis mce gene. The sequences are, therefore, quite different. The alignment of nucleic acid sequences illustrating the coding sequence identity and the differences in 5' and 3' sequences between the inserts of plasmid pZX7 (ref. 4) and pBCGcepX are shown in Figure 8. A chart listing endonuclease digestion sites for the 4.7 kb insert in pBCGcepX is shown in Figure 5. The 4740 bp DNA sequence was searched for possible open reading frames (ORFs) . An ORF was found between positions 1802 and 3383 of the sequence (Figure 4) . The DNA sequence of this open reading frame (SEQ ID No: 2) is shown in Figure 6. The ORF starts at ATG and there is a stop codon at TGA. The open reading frame is 1581 nucleotides long. Other putative ATG and GTG start codons in the DNA sequence encoding the mycobacterial protein of M. bovis BCG associated with cell binding and cell entry are shown boxed in Figure 4. The start codon of the MceP protein proposed by Arruda et al . , (ref. 4) is shown in Figure 4 at nucleotide position 2336. The open reading frame (SEQ ID No: 2) encodes a protein of 527 amino acids and a molecular weight of about 55 kDa. This may be a precursor protein with a signal sequence at the N-terminus which may be removed during post- translational processing. The sequence of the protein of M. bovis BCG associated with cell binding and cell entry is shown in Figure 7 (SEQ ID No: 3) . The translation frames for the ORFI of Mycobacterium tuberculosis mce gene (ref. 4) and the M. bovis BCG gene described herein are the same. Therefore, the MceP protein of Mycoj cteriura tuberculosis described in ref. 4 is also an internal polypeptide of the protein from M. bovis BCG provided herein. As explained above, a prior art gene involved in mediating cell entry of M. tuberculosis H37Ra (and described in reference 4) is quite different than that provided herein isolated for the first time from M. bovis BCG. Referring to Figure 9, there is illustrated the identification of a gene corresponding to the gene of M. bovis BCG as provided herein from clinical isolates of M. tuberculosis . The DNA from twelve different clinical isolates of M. tuberculosis was subjected to PCR using primer combination 4676/4677 (the positions relative to the published race gene of M. tuberculosis is shown at the bottom of Figure 9) and no amplification of a discrete product of the expected size was observed. In contrast, however, primer combinations 4676/4448 and 4414/4448 did yield fragments of about 600 bp (Figure 9) , which is the correct size as predicted from the sequence of the gene encoding the protein associated with cell binding and cell entry as provided herein of M. bovis BCG. Further PCR reactions using DNA from a M. tuberculosis clinical isolate TB243 (from the USA) were performed using primer combinations based upon the sequence of the inserted fragment in pBCGcepX derived from M. bovis BCG. Primer 4879 is designed based upon a sequence 3' to the putative stop codon at position 3383 (bottom of Figure 10) . PCR amplification using primer pair 4879/4865 in reactions with BCG and M. tuberculosis (TB243) DNA give a single amplified product of the expected size (approximately 2.6 kb) . PCR amplification using primer pair 4879/4812 also produced a band of the correct size but mispriming also produced other smaller products. Primer 4880 is designed to span the stop codon sequence in ORF1 described for the M. tuberculosis H37Ra race gene (ref. 4). Therefore, primer pair 4879/4880 should not yield an approximately 1.1 kb amplified product. Although misprimed products were observed, no 1.1 kb product was obtained in PCR reactions containing M. bovis BCG or M. tuberculosis clinical isolate DNA (Lanes F and I, Figure 10) . None of these primer combinations produced any PCR products using plasmid pZX7 as the template (ref. 4). This is expected since the insert in this plasmid is devoid of the 5 ' sequences observed for the M. bovis BCG gene encoding the mycobacterial protein associated with cell entry and cell binding, as provided herein. PCR reactions with other primer combinations such as 4676/4880, 4676/4881 and 4879/4882 were performed with plasmid pZX7 as well as with M. bovis BCG and M. tuberculosis (TB243) DNA. Amplification of pZX7 with oligomer pair 4676/4880 (primer 4880 spans a sequence flanking the stop codon of the published M. tuberculosis race ORF) yielded the expected sized DNA fragment. PCR amplification with the same primer pair leads to several amplification products from the BCG and M. tuberculosis clinical isolate DNA and was most likely due to non- specific priming. PCR using primers 4676/4881 (the latter spanning the sequence corresponding to 4880, in M. bovis BCG) yielded the correct sized band in M. bovis BCG, and M. tuberculosis, while no product was obtained for plasmid pZX7 (lanes N, Q and K, Figure 10) . Again, the products expected based on the BCG sequence were observed on PCR amplification using primers 4879 and 4882 (the latter constituting a sequence spanning the stop codon of the M. bovis BCG sequence) . It was clear from the PCR amplification experiments on M. bovis BCG DNA, using primers designed from the sequence of M. tuberculosis H37Ra (ref. 4), that the M. bovis BCG gene was different. The gene encoding a mycobacterial protein associated with cell binding and cell entry as provided herein is present in a number of clinical isolates from M. tuberculosis and encodes a protein of molecular weight of about 55,000. Thus, a prior art gene encoding a protein involved in mediating cell entry of M. tuberculosis H37Ra (ref. 4) may be a naturally occurring truncated variant of the more frequently encountered gene encoding a mycobacterial protein associated with cell binding and cell entry having a molecular weight of about 45,000 to about 60,000 and may reflect the different source of the prior art gene and the gene provided herein and may be due to cloning artifacts of the prior art work. In a diagnostic embodiment, the gene of the present invention is useful for specifically distinguishing mycobacteria from other pathogens. The use of the 4.7 kb insert of pBCGcepX as a probe in Southern blots of Xho I restriction enzyme digests of DNA from a number of M. tuberculosis clinical isolates and other pathogens, such as B . pertussis, M. ca tarrhalis , Pseudomonas aerugmosa and H. mfluenzae demonstrate the absence of homologous sequences in non-mycobacterial organisms. In contrast, all of the M. tuberculosis isolates tested have the specific 5 kb fragment described above and this distinguishes them from such other pathogenic organisms, (Figure 11) . Figure 12 shows the construction of expression plasmids for expression of the mycobacterial protein associated with cell binding and cell entry. £coRI- Hmdlll inserts are prepared by PCR amplification of chromosomal DNA using suitable primers to obtain the full length mcep gene having an ATG start codon and 5' truncation having a GTG start codon. The EcoRI-Hindlll inserts are inserted into plasmid pET-23b(+). The expression vector is transformed into E. coli cells and the mycobacterial protein expressed. It has been found that the protein express mainly on inclusion bodies. Western blot analysis (Figure 13) showed the highest level of expression with the most truncated sequence with expression levels decreasing with increasing length of the encoding gene. Figure 14 shows the results of an invasion assay wherein HeLa cells were contacted with latex beads coated with the mycobacterial protein (mcep) and with an irrelevant protein (BSA) . The electron micrographs show invasion (arrow m panel A) of the HeLa cells by the mcep-coated beads and no invasion by BSA. It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis, treatment of, for example, mycobacterial infections and the generation of lmmunological and other diagnostic reagents. A further non-limiting discussion of such uses is further presented below. 1. Vaccine Preparation and Use Immunogenic compositions, suitable to be used as vaccines, may be prepared from immunogenic mycobacterial protein associated with cell binding and cell entry encoded by the nucleic acid molecules as well as the nucleic acid molecules disclosed herein. The vaccine elicits an immune response which produces antibodies, including anti-cell binding and cell entry protein antibodies and cell-mediated immune responses. Immunogenic compositions including vaccines may be prepared as injectables, as liquid solutions or emulsions. The protein and nucleic acid molecules may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness of the vaccines. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intradermally or intramuscularly. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at ucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 1 to 95% of the protein and/or nucleic acid molecules. The vaccines are administered in a manner compatible with the dosage formulation, and m such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the protein and/or nucleic acid molecules. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and will vary according to the size of the host. The nucleic acid molecules encoding the mycobacterial protein associated with cell binding and cell entry may be used directly for immunization by administration of the DNA directly, for example, by injection for genetic immunization or by constructing a live vector such as Salmonella , adenovirus, poxvirus, vaccinia or poliovirus. A discussion of some live vectors that have been used to carry heterologous antigens to the immune system are discussed in, for example, O'Hagan (ref 5) . Processes for the direct injection of DNA into test subjects for genetic immunization are described in, for example, Ul er et al . (ref. 6). Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as an 0.05 to 1.0 percent solution in phosphate - buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses . Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally . Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and an HBsAg vaccine has been adjuvanted with alum. A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS) , as well as lipid A, and liposomes. To efficiently induce humoral immune responses and cell-mediated immunity, immunogens are often emulsified in adjuvants. 2. Use of Sequences as Hybridization Probes The nucleotide sequences of the present invention, encoding a mycobacterial protein associated with cell binding and cell entry, now allow for the identification and cloning of the corresponding genes from any species of Mycobacterium. The nucleotide sequences of the present invention are useful for their ability to selectively form duplex molecules with complementary stretches of other genes encoding a mycobacterial protein associated with cell binding and cell entry. Depending on the application, a variety of hybridization conditions may be employed to achieve varying degrees of selectivity of the probe toward these other genes. For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required such as 0.15 M to 0.9 M salt, at temperatures ranging from between about 30°C to about 55°C. Hybridization conditions can also be rendered more stringent by the addition of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily manipulated, and will generally be a method of choice depending on the desired results. In general, convenient hybridization temperatures in the presence of 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the target fragment, 37°C for 90 to 95% homology and 32°C for 85 to 90% homology. In a clinical diagnostic embodiment, the nucleic acid sequences of the genes of the present invention may be used in combination with an appropriate indicator, such as a label, for determining hybridization. A wide variety of appropriate indicators are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-labelling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or peroxidase may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a reaction visible to the human eye or spectrophoto etrically, to identify specific hybridization with samples containing gene sequences. The nucleic acid sequences of the present invention are useful as hybridization probes in solution hybridizations and in embodiments employing solid-phase procedures. In embodiments involving solid-phase procedures, the test DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e.g., serum, sputum, bronchoalveolar lavage fluid) or even tissues, is adsorbed or otherwise affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the genes of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label or indicator. It is preferred to select nucleic acid sequence portions which are conserved among various species of Mycobacterium . The selected probe may be at least 18bp and may be in the range of about 30 to about 90 bp, or greater. 3. Expression of the Genes Vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the genes encoding a mycobacterial protein associated with cell binding and cell entry. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, E. coli may be transformed using plasmid pBR322 which contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid or phage, must also contain, or be modified to contain, promoters which can be used by the host cell for expression. In addition, phage vectors containing replicon and control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda GEM™-11 may be utilized in making recombinant phage vectors which can be used to transform host cells, such as E. coli K12 strain LE392. Promoters commonly used in recombinant DNA construction include the β-lactamase (penicillinase) and lactose promoter systems and other microbial promoters, such as the T7 RNA polymerase promoter system as described in U.S. Patent No. 4,952,496. Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The particular promoter used will generally be a matter of choice depending upon the desired results. Hosts that are appropriate for expression of the genes provided herein may include bacteria such as E. coli , Bordetella , Bacillus species, Haemophilus, fungi, yeast, mammalian cells or the baculovirus expression system may be used. In accordance with this invention, it is preferred to make the mycobacterial protein associated with cell binding and cell entry by recombinant methods, particularly when the naturally occurring protein as purified from a culture of a species of Mycobacterium may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced protein in heterologous systems which can be isolated from the host in a manner to minimize contaminants. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore, endotoxin free. Such hosts include species of Bacillus and may be particularly useful for the production of non-pyrogenic mycobacterial protein associated with cell entry and cell binding and having a molecular weight of between about 45,000 to about 60,000. Biological Deposits A vector that contains the gene encoding a mycobacterial protein associated with cell binding and cell entry and having a molecular weight of between about 45,000 and about 60,000 from the M. bovis strain BCG that is described and referred to herein has been deposited with the American Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland 20852, USA, pursuant to the Budapest Treaty and prior to the filing of this application. Samples of the deposited vectors will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposit will be removed at that time. Viable samples will be provided if the depository is unable to dispense the same. The invention described and claimed herein is not to be limited in scope by the biological material deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar vectors that encode similar or equivalent antigens as described in this application are within the scope of the invention. Deposit Summary Deposit ATCC Date Deposited Designation Plasmid pBCGcepX 97511 April 11, 1996 | EXAMPLES The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terras are intended in a descriptive sense and not for purposes of limitation. Example 1 : This Example illustrates recombinant DNA methods. Restriction enzymes and cloning vectors were obtained from several sources including New England Biolabs, Gibco/BRL Life Technologies, Boehringer Mannheim and Stratagene. Reagents used in DNA isolation protocols were purchased from Sigma Biochemical. Most recombinant DNA manipulations were performed using standard protocols (ref. 7) . Sequencing was performed on an Applied Biosystems automated sequencer (370A) using dideoxy terminator chemistry with reagents in kit form and protocols supplied by the manufacturer. The synthesis of oligonucleotides used as primers was performed using an Applied Biosystems (380B) synthesizer. The synthetic polynucleotides were purified on OPC cartridges supplied by Applied Biosystems according to the manufacturers protocol. Example 2 : This Example describes the isolation of M. bovis BCG DNA. M. bovis BCG DNA was isolated using a modification of a technique described in the literature (ref. 8) . A starter culture of M. bovis BCG (Connaught) at A 6 oo of 3.4 (10 mL) was inoculated into 100 mL of Middlebrook 7H9 media (Difco Labs) supplemented with ADC enrichment (BBL, to 10%) and Tween 80 (Sigma, 0.05%). This culture was incubated for 14 days at 37°C in roller bottles, subsequently, 50 mL of culture was centrifuged (6,000 g for 10 min.) to pellet the cells. The pellet was resuspended 1 mL of TE buffer (10 mM Tris-HCl, pH7.5 and ImM EDTA) containing 200 μg/mL of Proteinase K (Gibco/BRL) and 10 mg/mL of hen egg white lysozyme (Sigma) . The suspension was incubated at 37°C for 60 min., spun down in a centrifuge (12,000 g for 1 min.) and the pellet resuspended in 1 ml of DNAzol™ reagent with vortexing. The suspension was transferred to a 2 mL screw capped tube filled to a quarter of its volume with glass beads (106 μm or finer) and vortexed vigorously for 10 min. The beads were then allowed to settle and the supernatant transferred to a fresh tube which was centrifuged for 10 minutes at room temperature. The resultant lysate was transferred to a new tube and 0.5 mL of 100% ethanol was added. The tube was inverted several times to mix and the mixture incubated at room temperature for 3 to 5 min. The tube was spun in a centrifuge (at 1,000 g for 2 min.) to pellet the DNA, the supernatant discarded, the pellet washed twice with 1 mL of 95% ethanol and then air dried at room temperature for 15 min. Finally, the pellet was dissolved in 0.2 mL of TE buffer and the quantity of DNA estimated by measuring the optical density at 260 nm in a spectrophotometer . This protocol yields approximately 80 μg of DNA. Example 3 : This Example describes the PCR amplification of the Mycobacterium bovis BCG gene encoding a mycobacterial protein associated with cell binding and cell entry. PCR amplification reactions were carried out on M. bovis BCG chromosomal DNA and pZX7 plasmid (pBluescript (+) from Stratagene) containing the 1535bp insert from Mycobacterium tuberculosis H37Ra supplied by Dr. Riley (ref. 4). The primers and their sequences used in PCR amplifications are listed in Table 1. The corresponding positions of these primers relative to the ORF1 encoding the race gene of Mycobacterium tuberculosis (as published in ref. 4) are illustrated in Figure 1 as a thick filled line. The amplifications were carried out using the "Hot Start procedure". Essentially a 40 μL reaction mix containing dNTP's (0.2 mM in 100 μL final volume), buffer and a pair of primers (100 pM of each) was prepared in thin walled eppendorf tubes. To each tube a bead of wax (PCRGem™, 100, Perkin-Elmer) was added and the tube heated to 70°C for 5 min. Subsequently, the tube was cooled to room temperature for 5 min. and a reaction mix (60 μL) containing buffer (supplied by manufacturer as a lOx concentration) , 1 unit of enzyme (Amplitaq™ or Taq'plus') and DNA template ( . bovis BCG chromosomal DNA 1 μg or 50 ng of plasmid) were added. The tubes where then placed in a Perkin-Elmer Cetus thermal cycler and a cycling sequence started based on the following parameters: Step 1: 93°C for 1 minute; Step 2: 93°C for 1 minute, 60°C for 1 minute; 72°C for 2 minutes; repeated for 10 cycles; Step 3: 93°C for 1 minute; 60°C for 1 minute; 72°C for 2 minutes (auto ext . 5 seconds) ; repeated for 20 cycles. Step 4: 72°C for 10 minutes; and Step 5: Maintain at 4°C. The tubes were stored at 4°C aliquots of lOμL were run on a 0.8% agarose gel, the bands visualized and photographed. Example 4 : This Example describes the construction of Mycobacterium bovis BCG libraries. Restriction enzyme digestion of M. bovis BCG DNA and subsequent Southern blot using a PCR amplified product (primer pairs 4414/4448; Lane 2; panel A, Figure 2) as a probe, indicated the presence of the gene on 1.5 kb and 5 kb fragments of Sal I and Xho I digests (Figure 3) . The corresponding bands were cut out and ligated into suitably digested pUC18 and pBluescript II sk(+) plasmids respectively. The libraries obtained after transformation of these plasmids into competent E . coli cells were probed for the gene by hybridization and two positive clones identified. These were grown, plasmid isolated and analyzed to yield two clones. Plasmid pBCGcepX contained an approximately 5 kb DNA insert containing the putative gene and another plasmid pBCGcepS containing a 1.5 kb Sal I insert which also hybridized to the mce gene specific probe. (Figure 4, dark filled arcs in panels A and B) . For Southern blot analysis an aliquot of M. bovis BCG DNA (1.2 μg) was digested with restriction endonucleases Eco R I, Hind III, Nde I, Bgl II, Dra III, Sac I, Sal I and Xho I (using 5 to 10 units each) . The digestion was carried out in a total volume of 20 μL for 4 hours using standard buffer and conditions. The digests were mixed with loading buffer and run on a 0.8% agarose gel (Figure 2, panel A) . The gel was transferred to a nylon membrane using standard reagents and protocols and the DNA fixed to the membrane. The amplification product of a PCR reaction on BCG DNA using primers 4414 and 4448 (Lane 4, panel A, Figure 1) was isolated by excising the corresponding band from the gel and extracting the DNA. The isolated DNA was labelled with 32p using the "Random priming system I" kit (New England Biolabs) for use as a hybridization probe. The membrane was prehybridized, hybridized with the labelled probe overnight at 55°C and subsequently washed. The blot was exposed to film overnight at room temperature and the autoradiograph developed (Figure 2: panel B) . M. bovis BCG DNA was digested with Sal I and Xho I restriction enzymes and the digests run out on a 0.8% agarose gel. Bands of 1.5 kb and 5 kb (panel B, Figure 2) were excised. The DNA was isolated from these agarose slices and ligated to Sal I digested pUC18 or Xho I digested pBluescript II sk(+) using T4 DNA ligase. The ligation reactions were used to transform competent E. coli K12 strain (TGI) cells and the colonies plated out on LB agar containing ampicillin. These were transferred to nitrocellulose membranes (Schleicher & Schuell) and probed with the labelled polynucleotide used in the above Southern blotting procedure. Positive colonies were identified, isolated, grown up and purified plasmid analyzed for inserted DNA following Sal I or Xho I digestion. Two clones, one containing an approximately 5 kb Xho I insert (pBCGcepX) and another containing a 1.5 kb Sal I (pBCGsepS) insert were identified. These clones were grown up, the plasmid isolated using a kit for high grade plasmid purification (Qiagen) and the genes sequenced. Example 5 : This Example describes the specific identification of M. tuberculosis from other pathogens by Southern hybridization using the gene encoding the mycobacterial protein associated with cell binding and cell entry. The isolated nucleic acid molecule encoding a mycobacterial protein associated with cell binding and cell entry and having a molecular weight of about 45 to about 60 kDa is useful in a diagnostic embodiment for specifically distinguishing mycobacteria from other pathogens . Chromosomal DNA (1 μg) from M. bovis BCG (Connaught) ; M. tuberculosis clinical isolates TB188, TB421 and TB458 from U.S.A., Uganda and Brazil respectively, and B. pertussis, B. ca tarrhalis , P. auregenosa and H. influenzae (Eagan strain) were digested with Xho I. The digests together with undigested chromosomal BCG DNA were electrophoresed on a 0.8% agarose gel and blotted onto a nylon membrane. The 5kb Xhol insert of plasmid pBCGcepX was isolated labelled with 32 P and used as a probe for the Southern blot. The blot was washed and exposed to film. The gel and auto radiograph after a 48 hour exposure are illustrated in Figure 11. Example 6: This Example describes the construction of an expression vector for expressing mycobacterial proteins associated with cell binding and cell entry. PCR amplification vectors were carried out on M. bovis BCG chromosomal DNA using primers to incorporate EcoRI and Hin lll restriction enzyme sites to facilitate cloning into an expression vector, using the procedure outlined in Example 3. A common primer was used for the 3 '-end while the sequence for the 5 ' -end depended on the length of the insert molecule. The primers are set forth in Table 3 below. A series of £coRI-HindiII inserts was prepared encoding the full length mycobacterial protein (ATG start codon) (1611 bp length) and 5' truncation of the full length sequence (GTG start codon) (1530 bp, 1326 bp and 1077 bp length) . The inserts were cloned into the EcoRI-Hindlll site of the pET-23b(+) vector from Novagen (see Figure 12). This vector incorporates a 11 amino acid T7 tag just upstream of the insert, permitting ready detection of any mycobacterial protein produced via Western blotting using a T7 tag antibody alkaline phosphatase conjugate from Novagen. Example 7 : This Example illustrates the expression of mycobacterial protein associated with cell binding and cell entry. The various plasmids prepared as described in Example 6 were transformed into competent E. coli BL21 (DE3)pLysS bacterial cells. Overnight cultures of bacteria containing the expression construct were grown in 100 ml fresh LB broth containing ampicillin and chloramphenicol for 3 hours and then induced with 1 mM IPTG. After 5 hours induction, the cells were pelleted and lysed by treatment with 1 mg/ml lysozyme in 50 mM Tris pH8/l mM EDTA followed by the addition of 0.1% deoxycholic acid. Chromosomal DNA was eliminated by digesting the lysate with 10 mg/ml DNAse I. The lysate was pelleted and washed several times in a 50 mM Tris pH8/l mM EDTA/100 mM NaCl buffer containing 1% Nonidet P-40 and 0.1% Triton X-100. The pellets, which include most of the invasin protein, were stored in 50 mM Tris pH8/l mM EDTA. The products were then analyzed by running protein gels and Western blots. Protein gel and Western blot analysis (Figure 13) showed that expression of the mycobacterial proteins was best with the plasmid construct containing the most truncated encoding sequence. Expression levels steadily decreased as more of the encoding sequence was used in the pET-23b expression construct. The construct carrying the full length encoding sequence showed very weak expression compared to the others. Example 8 : This Example illustrates invasion of HeLa cells by the expressed mycobacterial protein. E. coli expressing the full length mcep gene were grown in 100 ml of fresh LB broth containing ampicillin and chloramphenicol for 3 hours using as an inoculum, 10 ml of overnight culture of similar cells. The cells were induced with IPTG as described in Example 7, and harvested by centrifugation. The pellet was treated as described in Example 7. The pelleted inclusion bodies were taken up in 50 mM Tris-HCl (pH 8.0) and 1 mM EDTA. The pellet was resuspended by vortexing, incubating at 70°C for 10 min. followed by vortexing again. The suspension was centrifuged and the clear supernatant was added to 50 μl of resuspended beads (polybead polystyrene microsperes; 1 micron average size; Polyscience Inc.) which had been washed extensively in 50 mM Tris-HCl (pH 8.0) containing 1 mM DTT. The beads and supernatant were allowed to incubate at room temperature overnight with gentle mixing. Subsequently, the beads were separated by centrifugation and suspended in 1 ml of Tris buffer (50 mM) containing 10 mg/ml of BSA. The incubation was continued at room temperature for 30 min. before washing the beads twice in the same buffer. Finally the beads were resuspended in 1 ml of PBS. In the interim, HeLa cells were seeded into six well plates (4X105 cells per well) in DMEM containing 10% FCS . These were allowed to grow overnight in an incubator at 37°C and 5% C0 2 . The cells were washed with fresh media and then 100 μl of the latex beads in suspension were added to each well, incubated at 37°C for 4 hours, the media removed and the cells washed with PBS. The cells were fixed and prepared for electron microcopy (EM) using standard protocols by the EM operator at the University of Toronto EM facility. Electron micrographs showing individual cells containing beads (Panel A) or not containing beads (control - Panel B) are shown in Figure 14. Beads coated with a irrelevant protein, BSA, were used as control. The beads were prepared exactly as above, except for the initial step of incubating the beads with the solubilized mycobacterial protein. SUMMARY OF THE DISCLOSURE In summary of this disclosure, the present invention provides isolated nucleic acid molecules which encode a protein of a Mycobacterium strain associated with cell binding and cell entry and having a molecular weight of about 45 to about 60 kDa as well as the isolated and purified protein encoded thereby and fragments thereof. Modifications are possible within the scope of this invention. TABLE 1 : Sequence of PCR Primers PRIMER # SEQUENCE (5 '-3') SEQ. ID No. 4676 CCGCGGATCCGTGAACGCCGACATCAAGGCGACC 4 4677 CATGGATCCCTATGCGGCAGCCCCGCGGTCAGG 5 4414 GTATGTGTCGTTGACCACGCC 6 4417 ACTCCGGGCCTATGCGGCAGC 7 4447 GCGTGCATGCGTTCGGCGTGGACCGC 8 4448 TCAGGTCGATCGGCATCGTAGAAG 9 4812 CGAGCAGCGCAACGACGATGC 10 4865 CCGTTGCTGATGTGCGCGAG 11 4879 CATGGTCAGCCACTGCTACTAC 12 4880 GAACCACTCCGGGCCTATGCGGC 13 4881 GATCTCTGAGTTCGTCCTCAGCGAG 14 4882 CGACGGTTCCAGTGATTTTCATGG 15 4415 CCGTATCTGCAGCGGGGGGTC 16 TABLE 2 Amino Acid Composition of the Mycobacterial Cell Binding and Cell Entry Associated Protein of M. bovis BCG Amino Acids Number of Percentage Residues (MW) L - Leucine 53 10.7 R - Arginine 32 8.9 T - Threonine 45 8.1 A - Alanine 60 7.6 V - Valine 40 7.1 S - Serine 43 6.7 P - Proline 38 6.6 D - Aspartic Acid 29 6.0 I - Isoleucine 24 4.9 N - Asparagine 23 4.7 Y - Tyrosine 16 4.7 G - Glycine 45 4.6 F - Phenylalanine 14 3.7 E - Glutamic Acid 15 3.5 K - Lysine 15 3.4 Q - Glutamine 12 2.8 W - Tryptophan 7 2.3 M - Methionine 7 1.6 C - Cysteine 6 1.1 H - Histidine 3 0.7 Molecular weight for this protein = 55906.00 Table 3: Sequence of PCR Primers IDENTIFY SEQUENCE (5' -3') SEQ ID NO: 3 ' Primer ACGCAAGCTTGACGACGGTTCCAGTG 18 5' Primer CGATGAATTCTATGTCTTTTGGTCCTTCTTGG 19 full length (1611 bp) 5 ' Primer CGATGAATTCTGTGGAGGCCCCGTCGGTG 20 truncation 1 (1530 bp) 5 ' Primer CGATGAATTCTGTGCTGGTCTTCGCGCTC 21 truncation 2 (1326 bp) 5' Primer CGATGAATTCTGTGAACGCCGACATCAAG 22 truncation 3 (1077 bp) REFERENCES 1. Grange, J.M.; Gibson J; Osborn, T.W.; Collins, CH. and Yates, M.D. (1983), Tubercle 64: 129-139 2. PCT; WO 95/17511, Jacobs, W.R. Jr.; Bloom B.R., Collins, D.M., Delisle, G.W.; Pascopella, L. and Kawakami R.P. 3. Shepard, C.C. (1958), J. Exp. Med. 107: 237-45. 4.Arruda, S., Bonfim, G.; Huma-Byron, T. and Riley L.W. (1993), Science 261: 1454-1457. 5. O'Hagan, (1992), Clin. Pharraokinet. 22:1 6. Ulmer et al (1993) Curr. Opinion Invest. Drugs 2(9) 983- 989. 7. "Molecular Cloning: A Laboratory Manual", ed Sambrook. J.; Fritsch, E.F. and Maniatis, T. (1989) Cold Spring Harbour Laboratory Press. 8. Anderberg, R.J. Strachan, J.A. and Cangelosis, G.A. (1995), BioTechniques 18: 217-219

Claims: CLAIMS What we claim is: 1. An isolated nucleic acid molecule encoding a mycobacterial protein associated with cell binding and cell entry of a Λfycojbacteriu-τi strain and having a molecular weight of about 45 to about 60 kDa or a fragment thereof. 2. The nucleic acid molecule of claim 1 wherein said Mycobacterium species is a species of the tuberculosis complex. 3. The nucleic acid molecule of claim 2 wherein said yco-bacterium strain is a strain of Mycobacterium tuberculosis. 4. The nucleic acid molecule of claim 2 wherein said Mycobacterium strain is a strain of MycoJbacteriu-n bovis . 5. The nucleic acid molecule of claim 1 wherein said mycobacterial protein has substantially the following amino acid composition: Amino Acids Number of Residues Leucine 53 Arginine 32 Threonine 45 Alanine 60 Valine 40 Serine 43 Proline 38 Aspartic Acid 29 Isoleucine 24 Asparagine 23 Tyrosine 16 Glycine 45 Phenylalanine 14 Glutamic Acid 15 Lysine 15 Glutamine 12 Tryptophan 7 Methionine 7 Cysteine 6 Histidine 3 6. The nucleic acid molecule of claim 1 having a restriction map substantially as shown in Figure 5 for M. bovis strain BCG or the corresponding restriction map from other mycobacteria from the tuberculosis complex. 7. The nucleic acid molecule of claim 1 having a DNA sequence as shown in Figure 6 (SEQ ID No: 2) for M. bovis strain BCG or the sequence of the corresponding gene of other mycobacteria from the tuberculosis complex. 8. The nucleic acid molecule of claim 1 encoding an amino acid sequence as shown in Figure 7 (SEQ ID No: 3) for M. bovis strain BCG or the corresponding sequence in other mycobacteria from the tuberculosis complex. 9. An isolated DNA molecule amplifiable by polymerase chain reaction (PCR) by a pair of primers having the sequences of primers 4879 (SEQ ID No: 12) and 4882 (SEQ ID No: 15); or 4879 (SEQ ID No: 12) and 4865 (SEQ ID No: 11); or 4879 (SEQ ID No: 12) and 4812 (SEQ ID No: 10); or 5' primer SEQ ID NO 19 and 3' primer SEQ ID NO: 18 ; or 5 ' primer SEQ ID NO 20 and 3' primer SEQ ID NO: 18 ; or 5 ' primer SEQ ID NO 21 and 3' primer SEQ ID NO: 18 ; or 5 ' primer SEQ ID NO: 22 and 3' primer SEQ ID NO: 18. 10. The DNA molecule of claim 9 from a Mycobacterium strain of the tuberculosis complex. 11. The DNA molecule of claim 9 from a MycoJbacterium strain of Mycobacterium tuberculosis . 12. The DNA molecule of claim 9 from a Mycobacterium strain of Mycobacterium bovis. 13. A vector for transformation of a host comprising the nucleic acid molecule of claim 1 or the DNA molecule of claim 9. 14. The vector of claim 13 further comprising DNA sequences for expression of said protein in said host. 15. A transformed host containing an expression vector as claimed in claim 14. 16. A recombinant mycobacterial protein associated with cell binding and cell entry producible by the transformed host of claim 15 or a fragment of said protein. 17. A plasmid containing the gene encoding a mycobacterial protein associated with cell binding and cell entry of a strain of Mycobacterium having the identifying characteristics of plasmid pBCGcepX having ATCC Deposit No. 97511. 18. A method of determining the presence, in a sample, of nucleic acid encoding a mycobacterial protein associated with cell binding and cell entry and having a molecular weight between about 45 and about 60 kDa of a strain of Mycobacterium, which comprises the steps of: (a) contacting the sample with the nucleic acid molecule of claim 1 or the DNA molecule of claim 9 to produce duplexes comprising the nucleic acid molecule or DNA molecule and any nucleic acid molecule encoding the protein present in the sample and specifically hybridizable therewith; and (b) determining production of the duplexes. 19. A diagnostic kit for determining the presence, in a sample, of nucleic acid encoding a mycobacterial protein associated with cell binding and cell entry and having a molecular weight of between about 45 and about 60 kDa of a strain of Mycojbacteriu-ii, comprising: (a) the nucleic acid molecule of claim 1 or the DNA molecule of claim 9; (b) contacting means to contact the nucleic acid molecule or DNA molecule with the sample to produce duplexes comprising the nucleic acid molecule or DNA molecule and any nucleic acid molecule encoding the protein present in the sample and hybridizable with the nucleic acid or DNA molecule; and (c) identifying means to determine production of the duplexes. 20. A method for detection of a strain of Mycobacterium in a sample of tissue or body fluids, which comprises: providing a pair of primers which are primers 4879 (SEQ ID No: 12) and 4882 (SEQ ID No: 15); or 4879 (SEQ ID No. 12) and 4865 (SEQ ID No: 11); or 4879 (SEQ ID No: 12) and 4812 (SEQ ID No: 10) ; contacting the sample with the probes; performing a polymerase chain reaction to amplify an amplifiable nucleic acid sequence encoding a mycobacterial protein associated with cell binding or cell entry; and detecting the amplified DNA sequence which indicates the presence of a strain of yco-acterium in the sample. 21. An oligonucleotide primer selected from the group consisting of primers 4879 (SEQ ID No: 12), 4882 (SEQ ID No: 15), 4865 (SEQ ID No: 11), 4812 (SEQ ID No: 10); SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20; SEQ ID NO: 21 and SEQ ID NO: 22. 22. A method of producing a substantially pure recombinant mycobacterial protein associated with cell binding and cell entry and having a molecular weight between about 45 kDa and 60 kDa or fragment thereof, which comprises : transforming a host with a vector as claimed in claim 14; growing the transformed host to express the protein or fragment thereof, and isolating and purifying the protein free from other proteinaceous and cellular material. 23. The method of claim 22 wherein said fragment is expressed from a vector containing a gene having a 5'- truncation to a start codon. 24. An isolated and purified mycobacterial protein associated with cell binding and cell entry of a A2 Mycobacteri um strain and having a molecular weight of between about 45 and about 60 kDa or fragment thereof. 25. The protein of claim 24 which is that of a Mycobacterium strain of the tuberculosis complex. 26. The protein of claim 24 which is that of a Mycobacterium strain of Mycobacterium tuberculosis . 27. The protein of claim 24 which is that of a strain of Mycobacterium bovis. 28. The protein of claim 24 produced by the procedure of claim 22. 29. The protein of claim 24 having substantively the following amino acid composition: Amino Acids Number of Residues Leucine 53 Arginine 32 Threonine 45 Alanine 60 Valine 40 Serine 43 Proline 38 Aspartic Acid 29 Isoleucine 24 Asparagine 23 Tyrosine 16 Glycine 45 Phenylalanine 14 Glutamic Acid 15 Lysine 15 Glutamine 12 Tryptophan 7 Methionine 7 Cysteine 6 Histidine 3 30. An immunogenic composition, comprising at least one component selected from the group consisting of at least one isolated nucleic acid molecule as claimed in claim 1, at least one isolated DNA molecule as claimed in claim 9, at least one recombinant mycobacterial protein as claimed in claim 16 and at least one protein as claimed in claim 24 as an active component thereof, and a pharmaceutically acceptable carrier therefor. 31. A method of generating an immune response in a host, which comprises administering to the host an immunoeffective amount of the immunogenic composition of claim 30.

Inventors: ANAND NAVEEN N, KLEIN MICHEL H, ANAND, NAVEEN, N., KLEIN, MICHEL, H.
Applicants: ANAND NAVEEN N, CONNAUGHT LAB, KLEIN MICHEL H, ANAND, NAVEEN, N., CONNAUGHT LABORATORIES LIMITED, KLEIN, MICHEL, H.
Application year: 1997
Main classification: C12N15
IPC codes: A61K39, A61K48, C07K14, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33